2012•PubMedRequires access
[Expression of serum sICAM-1 in patients with primary hepatocellular carcinoma and its relationship with liver fibrosis].
Si-lang Zhou, Yongle Chen, Xin-zhao Peng, Yong-xing Zhao, Pei-zeng Xie, Ling Long, Xiaowen Chen, Kai-ming Dai
Open publisher page 1 citations
Abstract
AIM: To explore the clinical value of serum soluble intercellular adhesion molecule-1 (sICAM-1) in patients with primary hepatocellular carcinoma (PHC) and its relationship with liver fibrosis. METHODS: The serun sICAM-1, PC III, IV-C, LN and HA level of 45 cases of patients with PHC, 30 cases of benign tumor and 35 cases of healthy people were determined by ELISA, the relationship between sICAM-1 and liver fibrosis was analyzed. RESULTS: The serum sICAM-1, PC III, IV-C, LN and HA levels of the PHC group were significantly higher than that of the benign tumor group and normal control group, compared the difference was significant (P<0.05); The serum markers was no significant difference between the benign tumor group and normal control group (P>0.05); The serum sICAM-1 was positively correlated with the PC III, IV-C, LN and HA (γ= 0.683, 0.575, 0.573 and 0.539, P<0.05). CONCLUSION: Detection of serum sICAM-1 has important clinical significance for assessing the PHC patient's condition, early diagnosing and treating liver cancer.